for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cipla Ltd

CIPL.BO

Latest Trade

478.50INR

Change

5.25(+1.11%)

Volume

13,080

Today's Range

473.05

 - 

480.00

52 Week Range

389.55

 - 

585.50

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
473.25
Open
473.05
Volume
13,080
3M AVG Volume
58.04
Today's High
480.00
Today's Low
473.05
52 Week High
585.50
52 Week Low
389.55
Shares Out (MIL)
806.23
Market Cap (MIL)
387,110.20
Forward P/E
--
Dividend (Yield %)
0.62

Next Event

Q3 2020 Cipla Ltd Earnings Release

Latest Developments

More

Cipla Says Acquires Trademark Rights Of Vysov

Cipla Unit To Buy Remaining 40% Stake In Cipla Pharma Lanka From Citihealth Imports

Cipla Says U.S. FDA Inspection Ends With 4 Observations

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cipla Ltd

Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.

Contact Info

Mumbai Central

+91.22.24826000

https://www.cipla.com/

Executive Leadership

Yusuf K. Hamied

Non-Executive Chairman of the Board

Umang Vohra

Global Chief Executive Officer, Managing Director, Additional Director

Samina Vaziralli

Executive Vice Chairman of the Board

M. K. Hamied

Non-Executive Vice Chairman of the Board

Kedar Upadhye

Global Chief Financial Officer

Key Stats

2.21 mean rating - 39 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

142.8K

2018

147.5K

2019

163.6K

2020(E)

171.6K
EPS (INR)

2017

12.500

2018

18.460

2019

18.930

2020(E)

22.022
Price To Earnings (TTM)
23.48
Price To Sales (TTM)
2.30
Price To Book (MRQ)
2.48
Price To Cash Flow (TTM)
12.89
Total Debt To Equity (MRQ)
22.81
LT Debt To Equity (MRQ)
20.15
Return on Investment (TTM)
8.42
Return on Equity (TTM)
6.85

Latest News

Latest News

Indian shares end higher; Cipla top gainer on quarterly beat

Indian shares ended higher on Wednesday, with the broader NSE index breaching the 12,000 level for the first time since June 6 in intraday trade, helped by private banks and information technology companies.

UPDATE 1-India's Cipla Q3 profit falls as lean India sales, tax cost weigh

Cipla Ltd, India's second-largest generic drugmaker by market capitalisation, reported on Wednesday a 17.1 percent drop in quarterly profit, dragged down by higher tax expenses and weak sales in domestic market.

India's Cipla Q3 profit falls, lags estimate

Cipla Ltd, India's second-biggest generic drugmaker by market capitalisation, reported a 17.1 percent fall in third-quarter profit on Wednesday, hurt by higher tax expenses.

UPDATE 1-India's Cipla warns of headwinds in second half after Q2 profit miss

Cipla Ltd, India's second-largest drugmaker by market capitalisation, warned on Monday of "multiple headwinds" in the second half of the financial year after its quarterly profit fell short of analysts' estimates.

India's Cipla Q2 profit dips nearly 11 pct, misses estimate

Drugmaker Cipla Ltd posted a nearly 11 percent fall in second-quarter profit on Monday, much lower than analyst expectations.

UPDATE 1-India's Cipla Q1 profit trumps estimates on strong domestic growth

* India revenue up 22 pct (Adds detail, share movement, appointment of global COO)

India's Cipla Q1 profit trumps estimates

Cipla Ltd, India's third-largest drugmaker by market capitalisation, posted on Wednesday a more than 10 percent rise in its first-quarter profit, well above analysts' expectations.

UPDATE 1-India's Cipla posts Q4 profit, misses estimates

Cipla Ltd, India's second-biggest drugmaker by market capitalization, posted a fourth-quarter profit on Tuesday, but missed street estimates.

India's Cipla posts Q4 profit

Cipla Ltd, India's second-biggest drugmaker by market capitalization, posted a fourth-quarter profit on Tuesday, but missed analysts' estimates.

BRIEF-Cipla Partners With Mannkind For Marketing, Distribution Of Afrezza In India

* PARTNERS WITH MANNKIND FOR EXCLUSIVE MARKETING, DISTRIBUTION OF AFREZZA IN INDIA

BRIEF-Mannkind And Cipla Enter An Exclusive Marketing And Distribution Agreement For Afrezza® In India

* MANNKIND AND CIPLA ENTER AN EXCLUSIVE MARKETING AND DISTRIBUTION AGREEMENT FOR AFREZZA® IN INDIA

BRIEF-India's Cipla Gets Final Nod For Generic Vazculep, Others

* GETS FINAL NOD FOR GENERIC VAZCULEP, GENERIC PHENYLEPHRINE HYDROCHLORIDE INJECTION USP, 10 MG/ML SINGLE-DOSE VIAL, GENERIC AROMASIN

BRIEF-Cipla's JV Saba Investment Completes Disinvestment Of Stake Held In Al Jabal For Drugs And Medical Appliances

* CO'S JV SABA INVESTMENT COMPLETED DISINVESTMENT OF 99 PERCENT STAKE HELD IN AL JABAL FOR DRUGS AND MEDICAL APPLIANCES CO Source text: http://bit.ly/2GsCYiw Further company coverage:

BRIEF-India's Cipla Says Unit Launches Authorized Generic Version Of Aloxi In U.S.

* SAYS CO'S UNIT LAUNCHES AUTHORIZED GENERIC VERSION OF ALOXI IN U.S. Source text - http://bit.ly/2pEclNR Further company coverage:

BRIEF-Medrx says drug development and sale contract change

* Says it enters into a license contract with Cipla Ltd's wholly owned unit Cipla Technologies, LLC, instead of with Cipla Ltd's wholly owned unit Cipla USA Inc preciously, on development and sale of MRX-4TZT, transdermal patch for the treatment of spastic paralysis, due...

BRIEF-Cipla's Goa Unit FDA Inspection Finds Lab Records Deficient - TV

* CIPLA LTD GOA UNIT'S U.S. FDA INSPECTION FINDS THAT LAB RECORDS DEFICIENT, RECORDS DON'T INCLUDE COMPLETE TESTING DATA - TV Source text - http://bit.ly/2u1xLt3 Further company coverage:

Indian shares gain over 1 pct after 7 days of falls

Indian shares rose more than 1 percent on Thursday after seven consecutive sessions of declines, as market heavyweights such as Infosys recovered and as drug maker Cipla gained on solid earnings.

UPDATE 1-India's Cipla Q3 profit rises, but below estimates

Cipla Ltd, India's fourth-largest drugmaker by revenue, said third-quarter net profit rose 7 percent on strong domestic sales, but fell short of analysts' estimates.

BRIEF-Cipla Says Key Performance Metrics Inline With Co's Internal Targets

* SAYS KEY PERFORMANCE METRICS LOOK HEALTHY AND ARE INLINE WITH CO'S INTERNAL TARGETS Source text - http://bit.ly/2BhN3M6 Further company coverage:

India's Cipla Q3 profit rises about 7 pct

Cipla Ltd, India's fourth-largest drugmaker by revenue, posted an about 7 percent rise in third-quarter net profit on Wednesday, but missed analysts' estimates.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up